top biopharmaceuticals for glp-1 medication Major global pharma updates in July 2026 feature massive market movements in the obesity and segments, multi-billion dollar M&A deals, and new clinical milestones in regenerative and 2025 Pharma Trends: Keytruda, Mounjaro,

In addition, a head-to-head trial of semaglutide and liraglutide was conducted in the STEP 8 trial, with a mean weight loss of 17.1% in the semaglutide group, which was significantly more effective than liraglutide (mean weight loss of 6.6%)

But this trend reversed in 2018, with Keytrudas sales becoming higher than Opdivo's

Saxendas approval set a precedent in efficacy and pricing, with a cost of over $1,000 per month

Explore how GLP-1 therapy works, what to expect, and how Nexa Vitality supports your weight loss journey

The termination was not due to safety concerns but rather because the trial was deemed unlikely to meet its primary endpoint

From 2018 to 2021, Biktarvy's sales were $1.18 billion, $4.74 billion, $7.26 billion, and $8.62 billion, respectively